AUSTIN, Texas, Nov. 14, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced Dr. Amy Altman, vice president of Biodefense will present at the Defense Threat Reduction Agency's (DTRA) 2011 Chemical and Biological Defense Science and Technology (CBD S&T) Conference, which takes place November 14-16, 2011 in Las Vegas, Nevada.
During the conference, Dr. Altman will present "Fully automated xMAP®-based system for the multiplex detection of biothreat agents and emerging infectious diseases" in the Novel Next Generation System Platform Technologies session. Dr. Altman's presentation will take place on Tuesday, November 15, 2011 at 9:30 a.m. at the Mirage Las Vegas, Grand Ballroom DE.
Dr. Altman joined Luminex in 2007 and was appointed vice president of Luminex's Biodefense efforts in July 2010. Leveraging her background in chemical and biological defense and technology development, Dr. Altman is charged with strategy and driving growth in the biodefense market. Dr. Altman has also served as director of the Extramural Research Office and senior director of Research and Development for the Luminex Bioscience Group. She earned her BA degree in Microbiology and her MS degree in Microbiology from Miami University and earned her Ph.D. in Molecular Biology from Vanderbilt University.The 2011 CBD S&T Conference offers attendees the opportunity to examine the best, new, dynamic developments in basic and applied research within the chemical and biological defense landscape. Attendees will interact and collaborate with other researchers concerning the medical and physical sciences related to chemical and biological defense. Attendees will also have the opportunity to meet DTRA science and technology managers and other members of the chem-bio technologies team. For more information on the CBD S&T Conference, please visit: http://cbdstconf2011.sainc.com. About Luminex Corporation Luminex is committed to applying its passion for innovation to advancing healthcare and research worldwide. We are transforming global healthcare and life-science research through the development, manufacturing, and marketing of proprietary instruments and assays utilizing our xMAP open-architecture, multi-analyte platform and our MultiCode real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies that deliver cost-effective and rapid results to clinicians and researchers. Our technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. We are meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology please visit our website at http://www.luminexcorp.com. Contacts Corporate: Harriss T. CurrieChief Financial Officer and Vice President, FinanceLuminex Corporation firstname.lastname@example.org Investors: Matthew ScaloSr. Director, Investor RelationsLuminex Corporation email@example.com Media: Mimi TorringtonDirector, Marketing CommunicationsLuminex Corporation firstname.lastname@example.org Leslie Denson Porter Novelli Leslie.Denson@porternovelli.com512.241.2233 SOURCE Luminex Corporation